British medical devices maker ConvaTec Group Plc on Monday named Genus Plc’s top boss Karim Bitar as its chief executive officer and said Chairman Christopher Gent would retire from his role.
The company said outgoing Chief Executive Officer Rick Anderson will become executive chairman on a temporary basis from May 9 and will work with senior leadership until Bitar joins on Sept. 30. After that, Anderson will serve as interim non-executive chair.
The announcement, which confirms a Sky News report, comes after the catheter and colostomy bag maker reported disappointing annual results and launched a turnaround plan in February.
ConvaTec has been struggling to find its footing after being hit by logistical issues, recalls and a change in inventory policy by a leading customer, named by analysts as Medtronic .
The company’s former CEO Paul Moraviec, who guided ConvaTec through a $1.8 billion initial public offering in 2016, stepped down last October following warnings of lower sales and profitability, which had sent shares plummeting to a record low.
Analysts at Peel Hunt said that a turnaround is unlikely “overnight”, but Bitar’s track record of investing to deliver transformation at Genus bodes well for ConvaTec.
“There will, no doubt, be some investor regret that a successful CEO is moving on but Genus has a well-established wider management team and a clear strategy to which the board is fully committed,” Liberum analysts said.
Genus, an animal genetics company, said it has started a search for a new CEO.
By Shashwat Awasthi and Tanishaa Nadkar
Source: Reuters
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
